GCG and Insulin resistance: More specifically, for those with OAFLD with T2DM, the gut-derived hormone glucagon-like peptide-1 (GLP-1) alone or combined with other incretin analogs, such as the glucose-dependent insulinotropic polypeptide, lead to a favorable weight loss, decreased insulin resistance, and a decrease in transaminase levels and liver fat content [14,16,49,50,51].